Author:
Ghali Fady,Zhao Yibai,Patel Devin,Jewell Teresa,Yu Evan Y.,Grivas Petros,Montgomery R. Bruce,Gore John L.,Etzioni Ruth B.,Wright Jonathan L.
Reference35 articles.
1. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options;Schnipper;J Clin Oncol,2015
2. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials;Driscoll;Cancer J,2009
3. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials;Shi;Int J Clin Oncol,2009
4. FDA acceptance of surrogate end points for cancer drug approval: 1992–2019;Chen;JAMA Intern Med,2020
5. Center for Drug Evaluation and Research. Clinical trial endpoints for the approval of cancer drugs and biologics. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics.